Generic placeholder image

Current Diabetes Reviews

Author(s): Vincenza Di Stasi, Elisa Maseroli and Linda Vignozzi*

DOI: 10.2174/1573399818666211117123802

DownloadDownload PDF Flyer Cite As
Female Sexual Dysfunction in Diabetes: Mechanisms, Diagnosis and Treatment

Article ID: e171121198002 Pages: 6

  • * (Excluding Mailing and Handling)

Abstract

Female sexual dysfunction (FSD) is an underinvestigated comorbidity of diabetes mellitus, often not evaluated in diabetes clinics. Diabetic women should be encouraged to talk about this topic by their diabetologist, because these problems could be comorbid to cardio-metabolic alterations, as it happens in the male counterpart. This review summarizes evidence on sexual dysfunction characteristics in diabetic women, exploring possible underlying pathogenic mechanisms. The role of hypoglycemic drugs in this context was also evaluated. To date, no specific questionnaire has been designed for the assessment of sexual dysfunctions in diabetic female patients but the use of colour-doppler ultrasound of clitoral arteries has been highlighted as a useful tool for the assessment of cardiovascular risk in these women. Similarly, no specific guidelines are available for the treatment of FSD in the diabetic population but patients should be supported to have a healthy lifestyle and, in the absence of contraindications, can benefit from already approved treatments for FSD.

Keywords: Diabetes mellitus, female sexual dysfunction, hypoactive sexual desire disorder, hypoglycemic treatment, gender medicine, cardio-metabolic alterations.

[1]
International Diabetes Federation. IDF Diabetes Atlas. (Ninth Edition). 2019.
[2]
Zheng Y, Ley SH, Hu FB. Global aetiology and epidemiology of type 2 diabetes mellitus and its complications. Nat Rev Endocrinol 2018; 14(2): 88-98.
[http://dx.doi.org/10.1038/nrendo.2017.151]
[3]
Bancks MP, Casanova R, Gregg EW, Bertoni AG. Epidemiology of diabetes phenotypes and prevalent cardiovascular risk factors and diabetes complications in the National Health and Nutrition Examination Survey 2003-2014. Diabetes Res Clin Pract 2019; 158: 107915.
[http://dx.doi.org/10.1016/j.diabres.2019.107915]
[4]
Giraldi A, Kristensen E. Sexual dysfunction in women with diabetes mellitus. J Sex Res 2010; 47(2): 199-211.
[http://dx.doi.org/10.1080/00224491003632834]
[5]
Isidro ML. Sexual dysfunction in men with type 2 diabetes. Postgrad Med J 2012; 88(1037): 152-9.
[http://dx.doi.org/10.1136/postgradmedj-2011-130069]
[6]
Tamás V, Kempler P. Sexual dysfunction in diabetes. Handb Clin Neurol 2014; 126: 223-32.
[http://dx.doi.org/10.1016/B978-0-444-53480-4.00017-5]
[7]
Gandhi J, Dagur G, Warren K, et al. The role of diabetes mellitus in sexual and reproductive health: An overview of pathogenesis, evaluation, and management. Curr Diabetes Rev 2017; 13(6): 573-81.
[http://dx.doi.org/10.2174/1573399813666161122124017]
[8]
Kautzky-Willer A, Harreiter J, Pacini G. Sex and gender differences in risk, pathophysiology and complications of type 2 diabetes mellitus. Endocr Rev 2016; 37(3): 278-316.
[http://dx.doi.org/10.1210/er.2015-1137]
[9]
Thompson IM, Tangen CM, Goodman PJ, Probstfield JL, Moinpour CM, Coltman CA. Erectile dysfunction and subsequent cardiovascular disease. JAMA 2005; 294(23): 2996-3002.
[http://dx.doi.org/10.1001/jama.294.23.2996]
[10]
Corona G, Monami M, Boddi V, et al. Male sexuality and cardiovascular risk. A cohort study in patients with erectile dysfunction. J Sex Med 2010; 7(5): 1918-27.
[http://dx.doi.org/10.1111/j.1743-6109.2010.01744.x]
[11]
Corona G, Rastrelli G, Isidori AM, et al. Erectile dysfunction and cardiovascular risk: A review of current findings. Expert Rev Cardiovasc Ther 2020; 18(3): 155-64.
[http://dx.doi.org/10.1080/14779072.2020.1745632]
[12]
Maseroli E, Scavello I, Vignozzi L. Cardiometabolic risk and female sexuality-part I. Risk factors and potential pathophysiological underpinnings for female vasculogenic sexual dysfunction syndromes. Sex Med Rev 2018; 6(4): 508-24.
[http://dx.doi.org/10.1016/j.sxmr.2018.02.009]
[13]
Nowosielski K, Drosdzol A, Sipiński A, Kowalczyk R, Skrzypulec V. Diabetes mellitus and sexuality-does it really matter? J Sex Med 2010; 7(2 Pt 1): 723-35.
[http://dx.doi.org/10.1111/j.1743-6109.2009.01561.x]
[14]
Mazzilli R. Imbrogno N1, Elia J1, Delfino M1, Bitterman O1, Napoli A1, Mazzilli F. Sexual dysfunction in diabetic women: Prevalence and differences in type 1 and type 2 diabetes mellitus. Diabetes Metab Syndr Obes 2015; 8: 97-101.
[http://dx.doi.org/10.2147/DMSO.S71376]
[15]
Doruk H, Akbay E, Cayan S, Akbay E, Bozlu M, Acar D. Effect of diabetes mellitus on female sexual function and risk factors. Arch Androl 2005; 51(1): 1-6.
[http://dx.doi.org/10.1080/014850190512798]
[16]
Ahmed MR, Shaaban MM, Sedik WF, Mohamed TY. Prevalence and differences between type 1 and type 2 diabetes mellitus regarding female sexual dysfunction: A cross-sectional Egyptian study. J Psychosom Obstet Gynaecol 2018; 39(3): 176-81.
[http://dx.doi.org/10.1080/0167482X.2017.1318123]
[17]
Kizilay F, Gali HE, Serefoglu EC. Diabetes and sexuality. Sex Med Rev 2017; 5(1): 45-51.
[http://dx.doi.org/10.1016/j.sxmr.2016.07.002]
[18]
Peters SA, Huxley RR, Woodward M. Diabetes as risk factor for incident coronary heart disease in women compared with men: A systematic review and meta-analysis of 64 cohorts including 858,507 individuals and 28,203 coronary events. Diabetologia 2014; 57(8): 1542-51.
[http://dx.doi.org/10.1007/s00125-014-3260-6]
[19]
Peters SA, Huxley RR, Woodward M. Diabetes as a risk factor for stroke in women compared with men: A systematic review and meta-analysis of 64 cohorts, including 775,385 individuals and 12,539 strokes. Lancet 2014; 383(9933): 1973-80.
[http://dx.doi.org/10.1016/S0140-6736(14)60040-4]
[20]
Chatterjee S, Peters SA, Woodward M, et al. Type 2 diabetes as a risk factor for dementia in women compared with men: A pooled analysis of 2.3 million people comprising more than 100,000 cases of dementia. Diabetes Care 2016; 39(2): 300-7.
[21]
Al-Salameh A, Chanson P, Bucher S, Ringa V, Becquemont L. Cardiovascular disease in type 2 Diabetes: A review of sex-related differences in predisposition and prevention. Mayo Clin Proc 2019; 94(2): 287-308.
[http://dx.doi.org/10.1016/j.mayocp.2018.08.007]
[22]
Maseroli E, Scavello I, Vignozzi L. Cardiometabolic risk and female sexuality-part ii. understanding (and overcoming) gender differences: The key role of an adequate methodological approach. Sex Med Rev 2018; 6(4): 525-34.
[http://dx.doi.org/10.1016/j.sxmr.2018.03.004]
[23]
Corona G, Fagioli G, Mannucci E, et al. Penile doppler ultrasound in patients with erectile dysfunction (ED): Role of peak systolic velocity measured in the flaccid state in predicting arteriogenic ED and silent coronary artery disease. J Sex Med 2008; 5(11): 2623-34.
[http://dx.doi.org/10.1111/j.1743-6109.2008.00982.x]
[24]
Rastrelli G, Corona G, Lotti F, et al. Flaccid penile acceleration as a marker of cardiovascular risk in men without classical risk factors. J Sex Med 2014; 11(1): 173-86.
[http://dx.doi.org/10.1111/jsm.12342]
[25]
Maseroli E, Fanni E, Cipriani S, et al. Cardiometabolic risk and female sexuality: Focus on clitoral vascular resistance. J Sex Med 2016; 13(11): 1651-61.
[http://dx.doi.org/10.1016/j.jsxm.2016.09.009]
[26]
Cichocka E, Jagusiewicz M, Gumprecht J. Sexual dysfunction in young women with type 1 diabetes. Int J Environ Res Public Health 2020; 17(12): 4468.
[http://dx.doi.org/10.3390/ijerph17124468]
[27]
Bornstein J, Goldstein AT, Stockdale CK, et al. consensus vulvar pain terminology committee of the international society for the study of vulvovaginal disease (ISSVD); international society for the study of women’s sexual health (ISSWSH); international pelvic pain society (IPPS). 2015 ISSVD, ISSWSH, and IPPS consensus terminology and classification of persistent vulvar pain and vulvodynia. J Sex Med 2016; 13(4): 607-12.
[http://dx.doi.org/10.1016/j.jsxm.2016.02.167]
[28]
Kalra B, Kalra S, Bajaj S. Vulvodynia: An unrecognized diabetic neuropathic syndrome. Indian J Endocrinol Metab 2013; 17(5): 787-9.
[http://dx.doi.org/10.4103/2230-8210.117193]
[29]
Clayton AH, Goldstein I, Kim NN, et al. The international society for the study of women’s sexual health process of care for management of hypoactive sexual desire disorder in women. Mayo Clin Proc 2018; 93(4): 467-87.
[http://dx.doi.org/10.1016/j.mayocp.2017.11.002]
[30]
Esposito K, Maiorino MI, Bellastella G, Giugliano F, Romano M, Giugliano D. Determinants of female sexual dysfunction in type 2 diabetes. Int J Impot Res 2010; 22(3): 179-84.
[http://dx.doi.org/10.1038/ijir.2010.6]
[31]
Pontiroli AE, Cortelazzi D, Morabito A. Female sexual dysfunction and diabetes: A systematic review and meta-analysis. J Sex Med 2013; 10(4): 1044-51.
[http://dx.doi.org/10.1111/jsm.12065]
[32]
Kim NN. Sex steroid hormones in diabetes-induced sexual dysfunction: Focus on the female gender. J Sex Med 2009; 6(Suppl. 3): 239-46.
[http://dx.doi.org/10.1111/j.1743-6109.2008.01182.x]
[33]
Muka T, Nano J, Jaspers L, et al. Associations of steroid sex hormones and sex hormone-binding globulin with the risk of type 2 diabetes in women: A population-based cohort study and meta-analysis. Diabetes 2017; 66(3): 577-86.
[http://dx.doi.org/10.2337/db16-0473]
[34]
Kim C, Halter JB. Endogenous sex hormones, metabolic syndrome, and diabetes in men and women. Curr Cardiol Rep 2014; 16(4): 467.
[http://dx.doi.org/10.1007/s11886-014-0467-6]
[35]
Hua X, Li M, Pan F, Xiao Y, Cui W, Hu Y. Non-alcoholic fatty liver disease is an influencing factor for the association of SHBG with metabolic syndrome in diabetes patients. Sci Rep 2017; 7(1): 14532.
[http://dx.doi.org/10.1038/s41598-017-15232-9]
[36]
Olszanecka A, Kawecka-Jaszcz K, Czarnecka D. Association of free testosterone and sex hormone binding globulin with metabolic syndrome and subclinical atherosclerosis but not blood pressure in hypertensive perimenopausal women. Arch Med Sci 2016; 12(3): 521-8.
[http://dx.doi.org/10.5114/aoms.2016.59925]
[37]
Bąk E, Młynarska A, Sternal D, Kadłubowska M, Marcisz-Dyla E, Marcisz C. Sexual function and sexual quality of life in premenopausal women with controlled type 1 and 2 diabetes-preliminary study. Int J Environ Res Public Health 2021; 18(5): 2536.
[http://dx.doi.org/10.3390/ijerph18052536]
[38]
Longo M, Cirillo P, Scappaticcio L, et al. Female sexual function in young women with type 1 diabetes and additional autoimmune diseases. J Sex Med 2021; 18(1): 219-23.
[http://dx.doi.org/10.1016/j.jsxm.2020.10.006]
[39]
Corona G, Isidori AM, Aversa A, et al. Male and female sexual dysfunction in diabetic subjects: Focus on new antihyperglycemic drugs. Rev Endocr Metab Disord 2020; 21(1): 57-65.
[http://dx.doi.org/10.1007/s11154-019-09535-7]
[40]
Riveline JP, Franc S, Biedzinski M, et al. Sexual activity in diabetic patients treated by continuous subcutaneous insulin infusion therapy. Diabetes Metab 2010; 36(3): 229-33.
[http://dx.doi.org/10.1016/j.diabet.2010.01.004]
[41]
Maiorino MI, Bellastella G, Castaldo F, Petrizzo M, Giugliano D, Esposito K. Sexual function in young women with type 1 diabetes: The METRO study. J Endocrinol Invest 2017; 40(2): 169-77.
[http://dx.doi.org/10.1007/s40618-016-0542-5]
[42]
Wing RR, Bond DS, Gendrano IN III, et al. Effect of intensive lifestyle intervention on sexual dysfunction in women with type 2 diabetes: results from an ancillary Look AHEAD study. Diabetes Care 2013; 36(10): 2937-44.
[http://dx.doi.org/10.2337/dc13-0315]
[43]
Krysiak R, Drosdzol-Cop A, Skrzypulec-Plinta V, Okopień B. Sexual functioning and depressive symptoms in women with diabetes and prediabetes receiving metformin therapy: A pilot study. Exp Clin Endocrinol Diabetes 2017; 125(1): 42-8.
[44]
Bąk E, Marcisz C, Krzemińska S, Dobrzyn-Matusiak D, Foltyn A, Drosdzol-Cop A. Relationships of sexual dysfunction with depression and acceptance of illness in women and men with type 2 diabetes mellitus. Int J Environ Res Public Health 2017; 14(9): E1073.
[http://dx.doi.org/10.3390/ijerph14091073]
[45]
Bak E, Marcisz C, Krzeminska S, Dobrzyn-Matusiak D, Foltyn A, Drosdzol-Cop A. Does type 1 diabetes modify sexuality and mood of women and men? Int J Environ Res Public Health 2018; 15(5): E958.
[http://dx.doi.org/10.3390/ijerph15050958]
[46]
Ferraresi SR, Lara LA, Reis RM, Rosa e Silva AC. Changes in sexual function among women with polycystic ovary syndrome: A pilot study. J Sex Med 2013; 10(2): 467-73.
[http://dx.doi.org/10.1111/jsm.12011]
[47]
Benetti-Pinto CL, Ferreira SR, Antunes A Jr, Yela DA. The influence of body weight on sexual function and quality of life in women with polycystic ovary syndrome. Arch Gynecol Obstet 2015; 291(2): 451-5.
[http://dx.doi.org/10.1007/s00404-014-3423-1]
[48]
Assaly R, Gorny D, Compagnie S, et al. The favorable effect of empagliflozin on erectile function in an experimental model of type 2 diabetes. J Sex Med 2018; 15(9): 1224-34.
[http://dx.doi.org/10.1016/j.jsxm.2018.07.002]
[49]
Rosen R, Brown C, Heiman J. The Female Sexual Function Index (FSFI): A multidimensional self-report instrument for the assessment of female sexual function. J Sex Marital Ther 2000; 26: 191-208.
[http://dx.doi.org/10.1080/009262300278597]
[50]
Derogatis L, Clayton A, Lewis-D’Agostino D. Validation of the female sexual distress scale-revised for assessing distress in women with hypoactive sexual desire disorder. J Sex Med 2008; 5: 357-64.
[http://dx.doi.org/10.1111/j.1743-6109.2007.00672.x]
[51]
Amidu N, Alhassan A, Owiredu WKBA, Alidu H, Antuamwine BB, Abdul-Wahid M. Validity and reliability of the Golombok-Rust Inventory of Sexual Satisfaction (GRISS) in patients with type 2 diabetes. J Sex Marital Ther 2019; 45(2): 141-7.
[http://dx.doi.org/10.1080/0092623X.2018.1494647]
[52]
Maiorino MI, Bellastella G, Esposito K. Diabetes and sexual dysfunction: Current perspectives. Diabetes Metab Syndr Obes 2014; 7: 95-105.
[53]
Worsley R, Santoro N, Miller KK, Parish SJ, Davis SR. Hormones and female sexual dysfunction: Beyond estrogens and androgensdfindings from the Fourth International Consultation on Sexual Medicine. J Sex Med 2016; 13(3): 283-90.
[http://dx.doi.org/10.1016/j.jsxm.2015.12.014]
[54]
Clayton AH, Croft HA, Handiwala L. Antidepressants and sexual dysfunction: Mechanisms and clinical implications. Postgrad Med 2014; 126(2): 91-9.
[http://dx.doi.org/10.3810/pgm.2014.03.2744]
[55]
Lorenz T, Rullo J, Faubion S. Antidepressant-induced female sexual dysfunction. Mayo Clin Proc 2016; 91(9): 1280-6.
[http://dx.doi.org/10.1016/j.mayocp.2016.04.033]
[56]
Nastri CO, Lara LA, Ferriani RA, Rosa-E-Silva AC, Figueiredo JB, Martins WP. Hormone therapy for sexual function in perimenopausal and postmenopausal women. Cochrane Database Syst Rev 2013; (6): CD009672.
[http://dx.doi.org/10.1002/14651858.CD009672.pub2]
[57]
Ferreira CH, Dwyer PL, Davidson M, De Souza A, Ugarte JA, Frawley HC. Does pelvic floor muscle training improve female sexual function? a systematic review. Int Urogynecol J Pelvic Floor Dysfunct 2015; 26(12): 1735-50.
[http://dx.doi.org/10.1007/s00192-015-2749-y]
[58]
Labrie F, Archer DF, Koltun W. Efficacy of intravaginal Dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause. Menopause 2016; 23(3): 243-56.
[http://dx.doi.org/10.1097/GME.0000000000000571]
[59]
Morin M, Carroll MS, Bergeron S. Systematic review of the effectiveness of physical therapy modalities in women with provoked vestibulodynia. Sex Med Rev 2017; 5(3): 295-322.
[http://dx.doi.org/10.1016/j.sxmr.2017.02.003]